Coxib-inhibition of Duodenal Polyp Growth in FAP

Coxib-inhibition of Duodenal Polyp Growth in Familial Adenomatous Polyposis

Status

Terminated

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00844727

Enrollment

Registered

2009-02-16

Start date

2003-09-30

Completion date

2004-04-30

Last updated

2011-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duodenal Polyposis

Brief summary

Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.

Interventions

DRUGRofecoxib

DRUGplacebo

placebo pills

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* FAP patient with previous colectomy and confirmed polyposis

Exclusion criteria

* Pregnancy * Malignancy * NSAID hypersensitivity

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026